A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Active, not recruiting · Phase 3 · NCT05023980
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $43,160
- U.S. investigators named
- 10
- Sites paid
- 6
- Planned or actual enrollment
- 282
About the trial
- Sponsor
- Loxo Oncology, Inc. (with Eli Lilly and Company)
- Tested
- Pirtobrutinib (drug), Bendamustine (drug), Rituximab (drug)
- Dates
- Started 2021-09-23; completion 2027-10
- Results posted
- Yes
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated. Participation could last up to five years.
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $43,160 in research payments for this study in 2025 (14 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Richy Agajanian, M.D. Hematology & Oncology · Downey, CA
- Sumit Sawhney, M.D. Hematology & Oncology · Coral Springs, FL
- Zachary A. Sporn, MD Student in an Organized Health Care Education/Training Program · Boston, MA
- Alexandra Hall, MD Internal Medicine · Minneapolis, MN
- Forrest N. Gamble, MD Student in an Organized Health Care Education/Training Program · Durham, NC
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Girish S. Amin, MD Hematology · Brick, NJ
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Alejandro Duran Crane, MD Internal Medicine · Cleveland, OH
- Devora Lichtman, MD Internal Medicine · Cleveland, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Research Alliance Inc $19,459
- Advanced Research LLC $13,544
- New Jersey Center for Cancer Research LLC $7,104
- Innovative Clinical Research Institute LLC $1,582
- Helios Cr, Inc. $910
- Cleveland Clinic, OH $561
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.